Nabriva Therapeutics plc – NASDAQ:NBRV
Nabriva Therapeutics stock price monthly change
Nabriva Therapeutics stock price quarterly change
Nabriva Therapeutics stock price yearly change
Nabriva Therapeutics key metrics
Market Cap | 4.54M |
Enterprise value | N/A |
P/E | -0.08 |
EV/Sales | -0.12 |
EV/EBITDA | 0.09 |
Price/Sales | 0.12 |
Price/Book | 0.16 |
PEG ratio | N/A |
EPS | -19.93 |
Revenue | 35.58M |
EBITDA | -52.01M |
Income | -54.48M |
Revenue Q/Q | -1.03% |
Revenue Y/Y | 8.65% |
Profit margin | -137.63% |
Oper. margin | -133.5% |
Gross margin | 49.27% |
EBIT margin | -133.5% |
EBITDA margin | -146.15% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNabriva Therapeutics stock price history
Nabriva Therapeutics stock forecast
Nabriva Therapeutics financial statements
| Jun 2022 | 8.77M | -11.07M | -126.19% |
|---|---|---|---|
| Sep 2022 | 8.78M | -11.51M | -131.08% |
| Dec 2022 | 10.43M | -22.77M | -218.2% |
| Mar 2023 | 7.59M | -9.11M | -120.14% |
| 2022-08-03 | -5 | -4.5 |
|---|---|---|
| 2022-11-10 | -4.03 | -4.21 |
| Jun 2022 | 54893000 | 20.28M | 36.96% |
|---|---|---|---|
| Sep 2022 | 48240000 | 22.61M | 46.88% |
| Dec 2022 | 31765000 | 28.47M | 89.63% |
| Mar 2023 | 24338000 | 28.69M | 117.9% |
| Jun 2022 | -13.03M | -116K | -792K |
|---|---|---|---|
| Sep 2022 | -6.17M | -104K | 1.10M |
| Dec 2022 | -1.62M | -7K | -659K |
| Mar 2023 | -5.61M | -3K | -4.85M |
Nabriva Therapeutics alternative data
| Aug 2023 | 39 |
|---|---|
| Sep 2023 | 39 |
| Oct 2023 | 39 |
| Nov 2023 | 39 |
| Dec 2023 | 39 |
| Jan 2024 | 39 |
| Feb 2024 | 39 |
| Mar 2024 | 39 |
| Apr 2024 | 39 |
| May 2024 | 39 |
| Jun 2024 | 39 |
| Jul 2024 | 39 |
Nabriva Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Sep 2021 | 50000 | 0 |
| Dec 2021 | 107000 | 0 |
| Aug 2022 | 0 | 51839 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | SCHROEDER THEODORE R director, officer.. | Phantom Shares | 119,900 | N/A | N/A | ||
Option | DOLAN DANIEL officer: Chief Financial Officer | Phantom Shares | 41,600 | N/A | N/A | ||
Option | SCHROEDER THEODORE R director, officer.. | Stock Appreciation Right | 239,800 | $0.45 | $107,910 | ||
Option | SCHROEDER THEODORE R director, officer.. | Restricted Stock Units | 239,800 | N/A | N/A | ||
Option | GELONE STEVEN P. director, officer: President an.. | Phantom Shares | 46,700 | N/A | N/A | ||
Option | GELONE STEVEN P. director, officer: President an.. | Stock Appreciation Right | 93,400 | $0.45 | $42,030 | ||
Option | GELONE STEVEN P. director, officer: President an.. | Restricted Stock Units | 93,400 | N/A | N/A | ||
Option | NAFTZGER J. CHRISTOPHER officer: General Counsel and Co.. | Phantom Shares | 31,600 | N/A | N/A | ||
Option | NAFTZGER J. CHRISTOPHER officer: General Counsel and Co.. | Stock Appreciation Right | 63,200 | $0.45 | $28,440 | ||
Option | NAFTZGER J. CHRISTOPHER officer: General Counsel and Co.. | Restricted Stock Units | 63,200 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q3 2022 13 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 3 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 8 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 29 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Theodore R. Schroeder (1955) Chief Executive Officer & Director | $850,820 |
Dr. Steven P. Gelone Pharm. D (1968) Pres, Chief Operating Officer & Director | $652,160 |
| Dr. Colin Broom M.D. (1956) Director | $40,000 |
-
When is Nabriva Therapeutics's next earnings date?
Unfortunately, Nabriva Therapeutics's (NBRV) next earnings date is currently unknown.
-
Does Nabriva Therapeutics pay dividends?
No, Nabriva Therapeutics does not pay dividends.
-
How much money does Nabriva Therapeutics make?
Nabriva Therapeutics has a market capitalization of 4.54M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 31.06% to 35.67M US dollars. Nabriva Therapeutics made a loss 57.19M US dollars in net income (profit) last year or -$4.21 on an earnings per share basis.
-
What is Nabriva Therapeutics's stock symbol?
Nabriva Therapeutics plc is traded on the NASDAQ under the ticker symbol "NBRV".
-
What is Nabriva Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Nabriva Therapeutics?
Shares of Nabriva Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Nabriva Therapeutics's key executives?
Nabriva Therapeutics's management team includes the following people:
- Mr. Theodore R. Schroeder Chief Executive Officer & Director(age: 70, pay: $850,820)
- Dr. Steven P. Gelone Pharm. D Pres, Chief Operating Officer & Director(age: 57, pay: $652,160)
- Dr. Colin Broom M.D. Director(age: 69, pay: $40,000)
-
How many employees does Nabriva Therapeutics have?
As Jul 2024, Nabriva Therapeutics employs 39 workers.
-
When Nabriva Therapeutics went public?
Nabriva Therapeutics plc is publicly traded company for more then 8 years since IPO on 23 Jun 2017.
-
What is Nabriva Therapeutics's official website?
The official website for Nabriva Therapeutics is nabriva.com.
-
How can i contact Nabriva Therapeutics?
Nabriva Therapeutics can be reached via phone at +353 1 649 2000.
Nabriva Therapeutics company profile:
Nabriva Therapeutics plc
nabriva.comNASDAQ
39
Biotechnology
Healthcare
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Dublin, 1
CIK: 0001641640
ISIN: IE00BYQMW233
CUSIP: G63637105
